id stringlengths 14 74 | pmid stringclasses 398
values | id1 stringlengths 2 49 | id2 stringlengths 2 49 | id1_type stringclasses 3
values | id2_type stringclasses 3
values | is_in_same_sent bool 2
classes | min_sents_window int64 0 100 | text stringlengths 478 4.91k | relation_label stringclasses 9
values | novelty_label stringclasses 2
values | subject_id stringlengths 2 49 |
|---|---|---|---|---|---|---|---|---|---|---|---|
10491763#D003924-3175 | 10491763 | D003924 | 3175 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | true | 0 | @GeneOrGeneProductTgt$ Hepatocyte nuclear factor-6 @/GeneOrGeneProductTgt$: associations between genetic variability and @DiseaseOrPhenotypicFeatureSrc$ type II diabetes @/DiseaseOrPhenotypicFeatureSrc$ and between genetic variability and estimates of insulin secretion. The transcription factor @GeneOrGeneProductTgt$ h... | Association | No | 3175 |
10491763#3175-3630 | 10491763 | 3175 | 3630 | GeneOrGeneProduct | GeneOrGeneProduct | true | 0 | @GeneOrGeneProductSrc$ Hepatocyte nuclear factor-6 @/GeneOrGeneProductSrc$: associations between genetic variability and type II diabetes and between genetic variability and estimates of @GeneOrGeneProductTgt$ insulin @/GeneOrGeneProductTgt$ secretion. The transcription factor @GeneOrGeneProductSrc$ hepatocyte nuclear ... | None | null | None |
10491763#D005947-3175 | 10491763 | D005947 | 3175 | ChemicalEntity | GeneOrGeneProduct | true | 0 | @GeneOrGeneProductTgt$ Hepatocyte nuclear factor-6 @/GeneOrGeneProductTgt$: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion. The transcription factor @GeneOrGeneProductTgt$ hepatocyte nuclear factor (HNF)-6 @/GeneOrGeneProductTgt$ is an up... | None | null | None |
10491763#3175-3172 | 10491763 | 3175 | 3172 | GeneOrGeneProduct | GeneOrGeneProduct | false | 1 | @GeneOrGeneProductSrc$ Hepatocyte nuclear factor-6 @/GeneOrGeneProductSrc$: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion. The transcription factor @GeneOrGeneProductSrc$ hepatocyte nuclear factor (HNF)-6 @/GeneOrGeneProductSrc$ is an up... | None | null | None |
10491763#3175-3651 | 10491763 | 3175 | 3651 | GeneOrGeneProduct | GeneOrGeneProduct | false | 1 | @GeneOrGeneProductSrc$ Hepatocyte nuclear factor-6 @/GeneOrGeneProductSrc$: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion. The transcription factor @GeneOrGeneProductSrc$ hepatocyte nuclear factor (HNF)-6 @/GeneOrGeneProductSrc$ is an up... | None | null | None |
10491763#3175-6927 | 10491763 | 3175 | 6927 | GeneOrGeneProduct | GeneOrGeneProduct | false | 1 | @GeneOrGeneProductSrc$ Hepatocyte nuclear factor-6 @/GeneOrGeneProductSrc$: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion. The transcription factor @GeneOrGeneProductSrc$ hepatocyte nuclear factor (HNF)-6 @/GeneOrGeneProductSrc$ is an up... | None | null | None |
10491763#3175-rs74805019 | 10491763 | 3175 | rs74805019 | GeneOrGeneProduct | GeneOrGeneProduct | false | 3 | @GeneOrGeneProductSrc$ Hepatocyte nuclear factor-6 @/GeneOrGeneProductSrc$: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion. The transcription factor @GeneOrGeneProductSrc$ hepatocyte nuclear factor (HNF)-6 @/GeneOrGeneProductSrc$ is an up... | None | null | None |
10491763#D003924-3630 | 10491763 | D003924 | 3630 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | true | 0 | Hepatocyte nuclear factor-6: associations between genetic variability and @DiseaseOrPhenotypicFeatureSrc$ type II diabetes @/DiseaseOrPhenotypicFeatureSrc$ and between genetic variability and estimates of @GeneOrGeneProductTgt$ insulin @/GeneOrGeneProductTgt$ secretion. The transcription factor hepatocyte nuclear facto... | None | null | None |
10491763#D005947-D003924 | 10491763 | D005947 | D003924 | ChemicalEntity | DiseaseOrPhenotypicFeature | true | 0 | Hepatocyte nuclear factor-6: associations between genetic variability and @DiseaseOrPhenotypicFeatureTgt$ type II diabetes @/DiseaseOrPhenotypicFeatureTgt$ and between genetic variability and estimates of insulin secretion. The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several g... | Association | No | D005947 |
10491763#D003924-3172 | 10491763 | D003924 | 3172 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | true | 0 | Hepatocyte nuclear factor-6: associations between genetic variability and @DiseaseOrPhenotypicFeatureSrc$ type II diabetes @/DiseaseOrPhenotypicFeatureSrc$ and between genetic variability and estimates of insulin secretion. The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several g... | None | null | None |
10491763#D003924-3651 | 10491763 | D003924 | 3651 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | true | 0 | Hepatocyte nuclear factor-6: associations between genetic variability and @DiseaseOrPhenotypicFeatureSrc$ type II diabetes @/DiseaseOrPhenotypicFeatureSrc$ and between genetic variability and estimates of insulin secretion. The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several g... | None | null | None |
10491763#D003924-6927 | 10491763 | D003924 | 6927 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | true | 0 | Hepatocyte nuclear factor-6: associations between genetic variability and @DiseaseOrPhenotypicFeatureSrc$ type II diabetes @/DiseaseOrPhenotypicFeatureSrc$ and between genetic variability and estimates of insulin secretion. The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several g... | None | null | None |
10491763#D003924-rs74805019 | 10491763 | D003924 | rs74805019 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 2 | Hepatocyte nuclear factor-6: associations between genetic variability and @DiseaseOrPhenotypicFeatureSrc$ type II diabetes @/DiseaseOrPhenotypicFeatureSrc$ and between genetic variability and estimates of insulin secretion. The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several g... | None | null | None |
10491763#D005947-3630 | 10491763 | D005947 | 3630 | ChemicalEntity | GeneOrGeneProduct | true | 0 | Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of @GeneOrGeneProductTgt$ insulin @/GeneOrGeneProductTgt$ secretion. The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in t... | Positive_Correlation | No | D005947 |
10491763#3630-3172 | 10491763 | 3630 | 3172 | GeneOrGeneProduct | GeneOrGeneProduct | false | 2 | Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of @GeneOrGeneProductSrc$ insulin @/GeneOrGeneProductSrc$ secretion. The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in t... | None | null | None |
10491763#3630-3651 | 10491763 | 3630 | 3651 | GeneOrGeneProduct | GeneOrGeneProduct | false | 2 | Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of @GeneOrGeneProductSrc$ insulin @/GeneOrGeneProductSrc$ secretion. The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in t... | None | null | None |
10491763#3630-6927 | 10491763 | 3630 | 6927 | GeneOrGeneProduct | GeneOrGeneProduct | false | 2 | Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of @GeneOrGeneProductSrc$ insulin @/GeneOrGeneProductSrc$ secretion. The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in t... | None | null | None |
10491763#3630-rs74805019 | 10491763 | 3630 | rs74805019 | GeneOrGeneProduct | GeneOrGeneProduct | false | 4 | Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of @GeneOrGeneProductSrc$ insulin @/GeneOrGeneProductSrc$ secretion. The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in t... | None | null | None |
10491763#D005947-3172 | 10491763 | D005947 | 3172 | ChemicalEntity | GeneOrGeneProduct | false | 2 | Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion. The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in the pathogenesis of maturity-onset diabetes of t... | None | null | None |
10491763#D005947-3651 | 10491763 | D005947 | 3651 | ChemicalEntity | GeneOrGeneProduct | false | 2 | Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion. The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in the pathogenesis of maturity-onset diabetes of t... | None | null | None |
10491763#D005947-6927 | 10491763 | D005947 | 6927 | ChemicalEntity | GeneOrGeneProduct | false | 2 | Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion. The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in the pathogenesis of maturity-onset diabetes of t... | None | null | None |
10491763#D005947-rs74805019 | 10491763 | D005947 | rs74805019 | ChemicalEntity | GeneOrGeneProduct | false | 4 | Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion. The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in the pathogenesis of maturity-onset diabetes of t... | None | null | None |
10491763#3172-3651 | 10491763 | 3172 | 3651 | GeneOrGeneProduct | GeneOrGeneProduct | true | 0 | Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion. The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in the pathogenesis of maturity-onset diabetes of t... | None | null | None |
10491763#3172-6927 | 10491763 | 3172 | 6927 | GeneOrGeneProduct | GeneOrGeneProduct | true | 0 | Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion. The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in the pathogenesis of maturity-onset diabetes of t... | None | null | None |
10491763#3172-rs74805019 | 10491763 | 3172 | rs74805019 | GeneOrGeneProduct | GeneOrGeneProduct | false | 2 | Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion. The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in the pathogenesis of maturity-onset diabetes of t... | None | null | None |
10491763#3651-6927 | 10491763 | 3651 | 6927 | GeneOrGeneProduct | GeneOrGeneProduct | true | 0 | Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion. The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in the pathogenesis of maturity-onset diabetes of t... | None | null | None |
10491763#3651-rs74805019 | 10491763 | 3651 | rs74805019 | GeneOrGeneProduct | GeneOrGeneProduct | false | 2 | Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion. The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in the pathogenesis of maturity-onset diabetes of t... | None | null | None |
10491763#6927-rs74805019 | 10491763 | 6927 | rs74805019 | GeneOrGeneProduct | GeneOrGeneProduct | false | 2 | Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion. The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in the pathogenesis of maturity-onset diabetes of t... | None | null | None |
10661407#D008358-50489 | 10661407 | D008358 | 50489 | ChemicalEntity | GeneOrGeneProduct | true | 0 | @GeneOrGeneProductTgt$ Langerin @/GeneOrGeneProductTgt$, a novel @GeneOrGeneProductTgt$ C-type lectin @/GeneOrGeneProductTgt$ specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. We have identified a @GeneOrGeneProductTgt$ type II Ca2+-dependent lectin @/GeneOrGeneProdu... | Bind | Novel | D008358 |
10788334#D061325-672 | 10788334 | D061325 | 672 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | true | 0 | Founder mutations in the @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ gene in Polish families with @DiseaseOrPhenotypicFeatureSrc$ breast-ovarian cancer @/DiseaseOrPhenotypicFeatureSrc$. We have undertaken a hospital-based study, to identify possible @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ and BRCA... | Association | No | 672 |
10788334#672-675 | 10788334 | 672 | 675 | GeneOrGeneProduct | GeneOrGeneProduct | true | 0 | Founder mutations in the @GeneOrGeneProductSrc$ BRCA1 @/GeneOrGeneProductSrc$ gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible @GeneOrGeneProductSrc$ BRCA1 @/GeneOrGeneProductSrc$ and @GeneOrGeneProductTgt$ BRCA2 @/GeneOrGeneProductTgt$ founder mutation... | None | null | None |
10788334#D009369-672 | 10788334 | D009369 | 672 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 1 | Founder mutations in the @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ and BRCA2 founder mutations in the Polish population. The study group con... | None | null | None |
10788334#D001943-672 | 10788334 | D001943 | 672 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 1 | Founder mutations in the @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ and BRCA2 founder mutations in the Polish population. The study group con... | Association | No | 672 |
10788334#D010051-672 | 10788334 | D010051 | 672 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 1 | Founder mutations in the @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ and BRCA2 founder mutations in the Polish population. The study group con... | Association | No | 672 |
10788334#OMIM:604370-672 | 10788334 | OMIM:604370 | 672 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 1 | Founder mutations in the @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ and BRCA2 founder mutations in the Polish population. The study group con... | Association | Novel | 672 |
10788334#672-c|INS|5382|C | 10788334 | 672 | c|INS|5382|C | GeneOrGeneProduct | GeneOrGeneProduct | false | 5 | Founder mutations in the @GeneOrGeneProductSrc$ BRCA1 @/GeneOrGeneProductSrc$ gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible @GeneOrGeneProductSrc$ BRCA1 @/GeneOrGeneProductSrc$ and BRCA2 founder mutations in the Polish population. The study group con... | None | null | None |
10788334#672-rs28897672 | 10788334 | 672 | rs28897672 | GeneOrGeneProduct | GeneOrGeneProduct | false | 5 | Founder mutations in the @GeneOrGeneProductSrc$ BRCA1 @/GeneOrGeneProductSrc$ gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible @GeneOrGeneProductSrc$ BRCA1 @/GeneOrGeneProductSrc$ and BRCA2 founder mutations in the Polish population. The study group con... | None | null | None |
10788334#672-c|DEL|4153|A | 10788334 | 672 | c|DEL|4153|A | GeneOrGeneProduct | GeneOrGeneProduct | false | 5 | Founder mutations in the @GeneOrGeneProductSrc$ BRCA1 @/GeneOrGeneProductSrc$ gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible @GeneOrGeneProductSrc$ BRCA1 @/GeneOrGeneProductSrc$ and BRCA2 founder mutations in the Polish population. The study group con... | None | null | None |
10788334#D061325-675 | 10788334 | D061325 | 675 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | true | 0 | Founder mutations in the BRCA1 gene in Polish families with @DiseaseOrPhenotypicFeatureSrc$ breast-ovarian cancer @/DiseaseOrPhenotypicFeatureSrc$. We have undertaken a hospital-based study, to identify possible BRCA1 and @GeneOrGeneProductTgt$ BRCA2 @/GeneOrGeneProductTgt$ founder mutations in the Polish population. T... | None | null | None |
10788334#D061325-c|INS|5382|C | 10788334 | D061325 | c|INS|5382|C | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 3 | Founder mutations in the BRCA1 gene in Polish families with @DiseaseOrPhenotypicFeatureSrc$ breast-ovarian cancer @/DiseaseOrPhenotypicFeatureSrc$. We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families ... | Positive_Correlation | Novel | c|INS|5382|C |
10788334#D061325-rs28897672 | 10788334 | D061325 | rs28897672 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 3 | Founder mutations in the BRCA1 gene in Polish families with @DiseaseOrPhenotypicFeatureSrc$ breast-ovarian cancer @/DiseaseOrPhenotypicFeatureSrc$. We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families ... | Positive_Correlation | Novel | rs28897672 |
10788334#D061325-c|DEL|4153|A | 10788334 | D061325 | c|DEL|4153|A | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 3 | Founder mutations in the BRCA1 gene in Polish families with @DiseaseOrPhenotypicFeatureSrc$ breast-ovarian cancer @/DiseaseOrPhenotypicFeatureSrc$. We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families ... | Positive_Correlation | Novel | c|DEL|4153|A |
10788334#D009369-675 | 10788334 | D009369 | 675 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 1 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and @GeneOrGeneProductTgt$ BRCA2 @/GeneOrGeneProductTgt$ founder mutations in the Polish population. The study group consisted of 66 Polish families with @DiseaseOrPhe... | None | null | None |
10788334#D001943-675 | 10788334 | D001943 | 675 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 1 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and @GeneOrGeneProductTgt$ BRCA2 @/GeneOrGeneProductTgt$ founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who ha... | None | null | None |
10788334#D010051-675 | 10788334 | D010051 | 675 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 1 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and @GeneOrGeneProductTgt$ BRCA2 @/GeneOrGeneProductTgt$ founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who ha... | None | null | None |
10788334#OMIM:604370-675 | 10788334 | OMIM:604370 | 675 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 1 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and @GeneOrGeneProductTgt$ BRCA2 @/GeneOrGeneProductTgt$ founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who ha... | None | null | None |
10788334#675-c|INS|5382|C | 10788334 | 675 | c|INS|5382|C | GeneOrGeneProduct | GeneOrGeneProduct | false | 3 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and @GeneOrGeneProductSrc$ BRCA2 @/GeneOrGeneProductSrc$ founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who ha... | None | null | None |
10788334#675-rs28897672 | 10788334 | 675 | rs28897672 | GeneOrGeneProduct | GeneOrGeneProduct | false | 3 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and @GeneOrGeneProductSrc$ BRCA2 @/GeneOrGeneProductSrc$ founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who ha... | None | null | None |
10788334#675-c|DEL|4153|A | 10788334 | 675 | c|DEL|4153|A | GeneOrGeneProduct | GeneOrGeneProduct | false | 3 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and @GeneOrGeneProductSrc$ BRCA2 @/GeneOrGeneProductSrc$ founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who ha... | None | null | None |
10788334#D009369-c|INS|5382|C | 10788334 | D009369 | c|INS|5382|C | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 10 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with @DiseaseOrPhenotypicFeatureSrc$ cancer @/DiseaseOrPhenotypic... | None | null | None |
10788334#D009369-rs28897672 | 10788334 | D009369 | rs28897672 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 10 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with @DiseaseOrPhenotypicFeatureSrc$ cancer @/DiseaseOrPhenotypic... | None | null | None |
10788334#D009369-c|DEL|4153|A | 10788334 | D009369 | c|DEL|4153|A | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 10 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with @DiseaseOrPhenotypicFeatureSrc$ cancer @/DiseaseOrPhenotypic... | None | null | None |
10788334#D001943-c|INS|5382|C | 10788334 | D001943 | c|INS|5382|C | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 4 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with... | Positive_Correlation | Novel | c|INS|5382|C |
10788334#D001943-rs28897672 | 10788334 | D001943 | rs28897672 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 4 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with... | Positive_Correlation | Novel | rs28897672 |
10788334#D001943-c|DEL|4153|A | 10788334 | D001943 | c|DEL|4153|A | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 4 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with... | Positive_Correlation | Novel | c|DEL|4153|A |
10788334#D010051-c|INS|5382|C | 10788334 | D010051 | c|INS|5382|C | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 4 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with... | Positive_Correlation | Novel | c|INS|5382|C |
10788334#D010051-rs28897672 | 10788334 | D010051 | rs28897672 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 4 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with... | Positive_Correlation | Novel | rs28897672 |
10788334#D010051-c|DEL|4153|A | 10788334 | D010051 | c|DEL|4153|A | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | false | 4 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with... | Positive_Correlation | Novel | c|DEL|4153|A |
10788334#OMIM:604370-c|INS|5382|C | 10788334 | OMIM:604370 | c|INS|5382|C | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | true | 0 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with... | Positive_Correlation | Novel | c|INS|5382|C |
10788334#OMIM:604370-rs28897672 | 10788334 | OMIM:604370 | rs28897672 | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | true | 0 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with... | Positive_Correlation | Novel | rs28897672 |
10788334#OMIM:604370-c|DEL|4153|A | 10788334 | OMIM:604370 | c|DEL|4153|A | DiseaseOrPhenotypicFeature | GeneOrGeneProduct | true | 0 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with... | Positive_Correlation | Novel | c|DEL|4153|A |
10788334#c|INS|5382|C-rs28897672 | 10788334 | c|INS|5382|C | rs28897672 | GeneOrGeneProduct | GeneOrGeneProduct | true | 0 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with... | None | null | None |
10788334#c|INS|5382|C-c|DEL|4153|A | 10788334 | c|INS|5382|C | c|DEL|4153|A | GeneOrGeneProduct | GeneOrGeneProduct | true | 0 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with... | None | null | None |
10788334#rs28897672-c|DEL|4153|A | 10788334 | rs28897672 | c|DEL|4153|A | GeneOrGeneProduct | GeneOrGeneProduct | true | 0 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with... | None | null | None |
11009181#D001058-D010300 | 11009181 | D001058 | D010300 | ChemicalEntity | DiseaseOrPhenotypicFeature | true | 0 | @ChemicalEntitySrc$ Apomorphine @/ChemicalEntitySrc$: an underutilized therapy for @DiseaseOrPhenotypicFeatureTgt$ Parkinson's disease @/DiseaseOrPhenotypicFeatureTgt$. @ChemicalEntitySrc$ Apomorphine @/ChemicalEntitySrc$ was the first dopaminergic drug ever used to treat symptoms of @DiseaseOrPhenotypicFeatureTgt$ Par... | Negative_Correlation | Novel | D001058 |
11009181#D001058-D004298 | 11009181 | D001058 | D004298 | ChemicalEntity | ChemicalEntity | true | 0 | @ChemicalEntitySrc$ Apomorphine @/ChemicalEntitySrc$: an underutilized therapy for Parkinson's disease. @ChemicalEntitySrc$ Apomorphine @/ChemicalEntitySrc$ was the first @ChemicalEntityTgt$ dopaminergic drug @/ChemicalEntityTgt$ ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effect... | None | null | None |
11009181#D001058-D007980 | 11009181 | D001058 | D007980 | ChemicalEntity | ChemicalEntity | true | 0 | @ChemicalEntitySrc$ Apomorphine @/ChemicalEntitySrc$: an underutilized therapy for Parkinson's disease. @ChemicalEntitySrc$ Apomorphine @/ChemicalEntitySrc$ was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the... | Negative_Correlation | Novel | D001058 |
11009181#D001058-D018491 | 11009181 | D001058 | D018491 | ChemicalEntity | ChemicalEntity | true | 0 | @ChemicalEntitySrc$ Apomorphine @/ChemicalEntitySrc$: an underutilized therapy for Parkinson's disease. @ChemicalEntitySrc$ Apomorphine @/ChemicalEntitySrc$ was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the... | None | null | None |
11009181#D001058-D065098 | 11009181 | D001058 | D065098 | ChemicalEntity | ChemicalEntity | true | 0 | @ChemicalEntitySrc$ Apomorphine @/ChemicalEntitySrc$: an underutilized therapy for Parkinson's disease. @ChemicalEntitySrc$ Apomorphine @/ChemicalEntitySrc$ was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the... | None | null | None |
11009181#D001058-D004409 | 11009181 | D001058 | D004409 | ChemicalEntity | DiseaseOrPhenotypicFeature | true | 0 | @ChemicalEntitySrc$ Apomorphine @/ChemicalEntitySrc$: an underutilized therapy for Parkinson's disease. @ChemicalEntitySrc$ Apomorphine @/ChemicalEntitySrc$ was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the... | Negative_Correlation | Novel | D001058 |
11009181#D001058-D001523 | 11009181 | D001058 | D001523 | ChemicalEntity | DiseaseOrPhenotypicFeature | true | 0 | @ChemicalEntitySrc$ Apomorphine @/ChemicalEntitySrc$: an underutilized therapy for Parkinson's disease. @ChemicalEntitySrc$ Apomorphine @/ChemicalEntitySrc$ was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the... | None | null | None |
11009181#D004298-D010300 | 11009181 | D004298 | D010300 | ChemicalEntity | DiseaseOrPhenotypicFeature | true | 0 | Apomorphine: an underutilized therapy for @DiseaseOrPhenotypicFeatureTgt$ Parkinson's disease @/DiseaseOrPhenotypicFeatureTgt$. Apomorphine was the first @ChemicalEntitySrc$ dopaminergic drug @/ChemicalEntitySrc$ ever used to treat symptoms of @DiseaseOrPhenotypicFeatureTgt$ Parkinson's disease @/DiseaseOrPhenotypicFea... | None | null | None |
11009181#D007980-D010300 | 11009181 | D007980 | D010300 | ChemicalEntity | DiseaseOrPhenotypicFeature | false | 1 | Apomorphine: an underutilized therapy for @DiseaseOrPhenotypicFeatureTgt$ Parkinson's disease @/DiseaseOrPhenotypicFeatureTgt$. Apomorphine was the first dopaminergic drug ever used to treat symptoms of @DiseaseOrPhenotypicFeatureTgt$ Parkinson's disease @/DiseaseOrPhenotypicFeatureTgt$. While powerful antiparkinsonian... | None | null | None |
11009181#D018491-D010300 | 11009181 | D018491 | D010300 | ChemicalEntity | DiseaseOrPhenotypicFeature | false | 2 | Apomorphine: an underutilized therapy for @DiseaseOrPhenotypicFeatureTgt$ Parkinson's disease @/DiseaseOrPhenotypicFeatureTgt$. Apomorphine was the first dopaminergic drug ever used to treat symptoms of @DiseaseOrPhenotypicFeatureTgt$ Parkinson's disease @/DiseaseOrPhenotypicFeatureTgt$. While powerful antiparkinsonian... | None | null | None |
11009181#D065098-D010300 | 11009181 | D065098 | D010300 | ChemicalEntity | DiseaseOrPhenotypicFeature | false | 2 | Apomorphine: an underutilized therapy for @DiseaseOrPhenotypicFeatureTgt$ Parkinson's disease @/DiseaseOrPhenotypicFeatureTgt$. Apomorphine was the first dopaminergic drug ever used to treat symptoms of @DiseaseOrPhenotypicFeatureTgt$ Parkinson's disease @/DiseaseOrPhenotypicFeatureTgt$. While powerful antiparkinsonian... | None | null | None |
11009181#D004298-D007980 | 11009181 | D004298 | D007980 | ChemicalEntity | ChemicalEntity | false | 2 | Apomorphine: an underutilized therapy for Parkinson's disease. Apomorphine was the first @ChemicalEntitySrc$ dopaminergic drug @/ChemicalEntitySrc$ ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkin... | None | null | None |
11009181#D004298-D018491 | 11009181 | D004298 | D018491 | ChemicalEntity | ChemicalEntity | false | 3 | Apomorphine: an underutilized therapy for Parkinson's disease. Apomorphine was the first @ChemicalEntitySrc$ dopaminergic drug @/ChemicalEntitySrc$ ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkin... | None | null | None |
11009181#D004298-D065098 | 11009181 | D004298 | D065098 | ChemicalEntity | ChemicalEntity | false | 3 | Apomorphine: an underutilized therapy for Parkinson's disease. Apomorphine was the first @ChemicalEntitySrc$ dopaminergic drug @/ChemicalEntitySrc$ ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkin... | None | null | None |
11009181#D004298-D004409 | 11009181 | D004298 | D004409 | ChemicalEntity | DiseaseOrPhenotypicFeature | false | 5 | Apomorphine: an underutilized therapy for Parkinson's disease. Apomorphine was the first @ChemicalEntitySrc$ dopaminergic drug @/ChemicalEntitySrc$ ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkin... | None | null | None |
11009181#D004298-D001523 | 11009181 | D004298 | D001523 | ChemicalEntity | DiseaseOrPhenotypicFeature | false | 6 | Apomorphine: an underutilized therapy for Parkinson's disease. Apomorphine was the first @ChemicalEntitySrc$ dopaminergic drug @/ChemicalEntitySrc$ ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkin... | None | null | None |
11009181#D007980-D018491 | 11009181 | D007980 | D018491 | ChemicalEntity | ChemicalEntity | false | 1 | Apomorphine: an underutilized therapy for Parkinson's disease. Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administrat... | None | null | None |
11009181#D007980-D065098 | 11009181 | D007980 | D065098 | ChemicalEntity | ChemicalEntity | false | 1 | Apomorphine: an underutilized therapy for Parkinson's disease. Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administrat... | None | null | None |
11009181#D007980-D004409 | 11009181 | D007980 | D004409 | ChemicalEntity | DiseaseOrPhenotypicFeature | true | 0 | Apomorphine: an underutilized therapy for Parkinson's disease. Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administrat... | Positive_Correlation | No | D007980 |
11009181#D007980-D001523 | 11009181 | D007980 | D001523 | ChemicalEntity | DiseaseOrPhenotypicFeature | false | 1 | Apomorphine: an underutilized therapy for Parkinson's disease. Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administrat... | None | null | None |
11009181#D018491-D065098 | 11009181 | D018491 | D065098 | ChemicalEntity | ChemicalEntity | true | 0 | Apomorphine: an underutilized therapy for Parkinson's disease. Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administrat... | None | null | None |
11009181#D018491-D004409 | 11009181 | D018491 | D004409 | ChemicalEntity | DiseaseOrPhenotypicFeature | false | 2 | Apomorphine: an underutilized therapy for Parkinson's disease. Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administrat... | None | null | None |
11009181#D018491-D001523 | 11009181 | D018491 | D001523 | ChemicalEntity | DiseaseOrPhenotypicFeature | false | 3 | Apomorphine: an underutilized therapy for Parkinson's disease. Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administrat... | None | null | None |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 266